# Article information:

Full article: Cancer immunotherapy based on blocking immune suppression mediated by an immune modulator LAIR-1
<https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1740477>

# Article summary:

1. LAIR-1 is an inhibitory receptor containing ITIM motifs that is expressed on many immune cell subsets and can negatively regulate cell activation.

2. Collagens are functional ligands for LAIR-1 and can directly inhibit immune cell activation in vitro.

3. Overexpression of collagens in tumors correlates with enhanced metastatic capacity and unfavorable clinical outcome.

# Article rating:

Appears well balanced: The article presents the information in a reliable and balanced way, without biases and prejudices. The claims made in the article are well supported and, where applicable, all sides of the argument are given opportunity to present their point of view. The article appears trustworthy and reliable.

# Article analysis:

The article is generally reliable and trustworthy, as it provides a comprehensive overview of the role of LAIR-1 in cancer immunotherapy based on blocking immune suppression mediated by an immune modulator. The article cites relevant research studies to support its claims, which adds to its credibility. Furthermore, the article does not appear to be biased or one-sided, as it presents both sides of the argument equally and objectively. However, there are some points that could be improved upon. For example, the article does not explore any potential risks associated with using LAIR-1 for cancer immunotherapy, nor does it discuss any possible counterarguments or alternative approaches that could be taken instead. Additionally, while the article does provide evidence for its claims, more evidence could be provided to further strengthen its arguments. Finally, there is no promotional content present in the article, which adds to its trustworthiness and reliability.

# Topics for further research:

* Potential risks of LAIR-1 cancer immunotherapy
* Alternative approaches to cancer immunotherapy
* Adverse effects of LAIR-1 cancer immunotherapy
* Evidence for LAIR-1 cancer immunotherapy
* Pros and cons of LAIR-1 cancer immunotherapy
* Clinical trials of LAIR-1 cancer immunotherapy

# Report location:

<https://www.fullpicture.app/item/fbe4b15d9cc9209f13b2f8cc6ef645dc>